FDA approves AstraZeneca's Imfinzi combination for high-risk bladder cancer
The U.S. Food and Drug Administration approved AstraZeneca's (NYSE:AZN) blockbusting immunotherapy Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, marking a major regulatory expansion for the company’s oncology franchise into earlier-stage disease.










